Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)

OBJECTIVE: To compare, in real‐life settings, the retention rates of initial anti‐tumor‐necrosis factor (TNF) treatments (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) used as first‐line biotherapy for axial spondyloarthritis (axSpA), and evaluate treatment switches to another anti‐TNF in...

Descripción completa

Detalles Bibliográficos
Autores principales: Soubrier, Martin, Pereira, Bruno, Fan, Angelique, Frayssac, Thomas, Couderc, Marion, Malochet‐Guinamand, Sandrine, Mathieu, Sylvain, Tatar, Zuzana, Tournadre, Anne, Dubost, Jean‐Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585683/
https://www.ncbi.nlm.nih.gov/pubmed/30168265
http://dx.doi.org/10.1111/1756-185X.13375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585683/
https://www.ncbi.nlm.nih.gov/pubmed/30168265
http://dx.doi.org/10.1111/1756-185X.13375

Ejemplares similares